Li Li, Commissioner of China's National Medical Products Administration (NMPA), and Mette Aaboe Hansen, interim director ...

The Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective ...

Danish allergy immunotherapy specialist ALK Abello has entered into a strategic license agreement with US-based ARS ...

Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi ...

According to the Swedish pharma trade group Lif, it is positive that, in the updated life science strategy, the government expresses an ambition for Sweden to become more attractive for research ...

In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...

Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

Pfizer plans to invest $1 billion in China by 2030 to support innovation, diagnostics, and the biotech sector, aligning with ...

Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new ...

Viracta Therapeutics has announced a restructuring to focus on its lead oncology candidate, nana-val, targeting EBV-positive ...

AlloVir will merge with Kalaris Therapeutics in an all-stock transaction, with Kalaris shareholders holding a 75% stake in ...

GEN1047, GEN3017, and GEN1056—to refocus resources, following its recent $1.8 billion acquisition of ProfoundBio. The move ...